Novartis sells phase 3 rare disease drug to Pharming | Fierce Biotech
Novartis pays $100M for Mallinckrodt's priority review voucher
HazardEx - Novartis plant leak causes hospitalisation of six workers
Moving Away from Asthma and COPD, Novartis Hones in on 20 Approvals by 2026 | BioSpace
Novartis to prioritise U.S. market, unfazed by drug pricing pushback | Reuters
Novartis signs deal with BeiGene to bolster immunotherapy pipeline
Alcon becomes a separately traded standalone company | Novartis
Investors | Novartis
Novartis Annual Results | Novartis
Teva Pharma appoints Novartis, Biogen vet as new president and CEO – PharmaLive
Six Former and Current Novartis AG Execs Charged With Bribing Doctors in Korea | BioSpace
Novartis' Zykadia nears first-line lung cancer label - PMLiVE
NOVN: Novartis AG Stock Price Quote - SIX Swiss Ex - Bloomberg
Novartis is shutting down Colorado plant, laying off 400 employees after overestimating gene therapy demand | Fierce Pharma
A World of Opportunity
Drug used to treat advanced prostate cancer in short supply, Novartis says - CBS News
Novartis - Wikipedia
It Paid Doctors Kickbacks. Now, Novartis Will Pay a $678 Million Settlement. - The New York Times
Novartis's nuclear vision starts to take shape | Evaluate
